Home
About Us
Overview
R&D Facilities
Management Team
Antibiotic Resistance
Lead Product
R&D Facilities
News
Contact Us
Contact Us
Careers
Home
About Us
Overview
R&D Pipeline
Leadership Team
Antibiotic Resistance
Lead Products
Lysigen
Phagelux
R&D Facilities
News
Contact Us
Contact Us
Careers
En
En
中文
News
Home
News
Phagelux Subsidiary Company Name Change to Lysigen
Shanghai, Wuhan, November 12, 2021: Phagelux, Inc. is proud to announce the change of name of its Wuhan-based subsidiary to Lysigen (Chinese Name).
2021-11-12
Phagelux Staph Lysin Out-licensing Announcement
Montreal, Shanghai, Wuhan, November 4, 2021: Phagelux, Inc. is proud to announce the out-licensing of its staphylococcus lysin to Shanghai Pharmaceutical Holdings Co. (hereinafter referred to as “SPH”, 601607.SH; 2607.HK) for in vivo applications. This licensing agreement is limited to the greater China market.
2021-11-04
LysiThru™ Public Announcement
Montreal, Shanghai, Wuhan, October 11, 2021: Phagelux, Inc. is proud to announce the trademark filing of LysiThru, our novel high through put screening system for rapidly developing lysins effective against both gram positive and gram negativebacteria.
2021-10-11
Phagelux CEO Mark Engel interviewed at JP Morgan Conference
Jan.16, 2020 Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.
2020-01-06
Copyright © PrecisioBiotix
support:
极速建站